Healthcare / Drug Manufacturers - GeneralTaipei Exchange
$53.90
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $4.4M · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.1B
P/E
117.2x
↑EV/EBITDA
49.0x
↑ROE
2.1%
↑Gross Margin
52.4%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+43.1%
FCF CAGR
—
FCF margin
2.0%
FCF / Net income
0.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $222.0M · net income $25.0M · FCF $4.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $222.0M | $222.0M | $130.7M | $117.9M | $75.7M |
| Net Income | $25.0M | $25.0M | $14.5M | $9.1M | $-3.8M |
| EBITDA | $59.6M | $59.6M | $32.2M | $26.1M | $10.7M |
| EPS | — | — | 0.36 | 0.30 | -0.15 |
| Gross Margin | 52.4% | 52.4% | 53.5% | 54.8% | 47.3% |
| Operating Margin | 6.6% | 6.6% | 6.2% | 5.4% | -4.8% |
| Net Margin | 11.3% | 11.3% | 11.1% | 7.8% | -5.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.26 | 0.13 | 0.34 |
| Current Ratio | 10.68 | 10.68 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.4M | $4.4M | $-160.6M | $8.1M | $-27.9M |
| Returns | |||||
| ROE | 2.1% | 2.1% | 2.5% | 2.2% | -2.8% |
| Valuation | |||||
| P/E | 117.17 | 117.17 | 110.23 | — | — |
| EV/EBITDA | 49.04 | 49.04 | 49.33 | — | — |
| P/B | 2.63 | 2.63 | 2.78 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 69.9% | 69.9% | 10.9% | 55.6% | — |
| EPS Growth | — | — | 20.0% | 295.1% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+5.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.36 → n/d
Residual
+5.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.